Humanitas Mirasole S.p.A.
- Address
- Via Francesco Nava 31, 20159 Milan, Italy
Neurocritical Care and Brain Injury Research
At Humanitas Mirasole S.p.A. in Milan, clinical trials in nervous system diseases focus on traumatic brain injury and recovery after serious neurological damage. These studies are designed to assess whether new approaches can improve safety, tolerability, and clinical outcomes for critically injured patients.
- Subacute traumatic brain injury
- Moderate to severe brain injury recovery
- Testing an intranasal therapy for neurological support
This research aims to expand treatment options for patients with acute brain injury while improving how neurological recovery is supported in the hospital setting.
Gynecologic Oncology and Ovarian Cancer Research
A major part of the site’s work centers on neoplasms, especially ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Many trials are evaluating new therapies and maintenance strategies to improve disease control, delay progression, and extend survival in recurrent or platinum-resistant disease.
- Advanced and recurrent ovarian cancer
- Platinum-resistant ovarian cancer
- Maintenance treatment after initial therapy
- Testing targeted and antibody-based treatments
The research portfolio includes studies in biomarker-selected populations, reflecting a strong interest in more personalized treatment for women with difficult-to-treat gynecologic cancers.
Endometrial, Cervical, and Vulvar Cancer Studies
Another prominent area at Humanitas Mirasole S.p.A. is female urogenital diseases, with trials in endometrial cancer, cervical cancer, and vulvar cancer. These studies are exploring new treatment combinations, maintenance options, and better ways to identify patients most likely to benefit from targeted therapy.
- Advanced or recurrent endometrial cancer
- Locally advanced and metastatic cervical cancer
- Vulvar cancer and HPV-related lesions
- Evaluating treatment effectiveness and disease response
The site is actively involved in research that combines precision medicine with clinical outcome assessment, aiming to improve care across multiple gynecologic malignancies.
Precision Medicine in Solid Tumors
Several trials at this Milan site address a broad range of solid tumors, including head and neck cancer, pancreatic cancer, colorectal cancer, and lung cancer. The main goal is to test new targeted therapies and immunotherapy-based strategies for patients with advanced or relapsed disease.
- Advanced solid tumors with specific molecular features
- Head and neck squamous cell carcinoma
- Pancreatic and colorectal cancers
- Assessing tumor response and survival outcomes
This research reflects a strong precision-oncology focus, with studies designed to match therapies to tumor biology and improve outcomes in hard-to-treat cancers.
Infectious Disease, Critical Care, and Supportive Treatment Research
The site also contributes to bacterial infections and mycoses research, alongside studies in pathological conditions, signs and symptoms seen in critically ill patients. These trials often aim to improve survival, optimize supportive care, or refine treatment approaches in intensive care and other high-risk settings.
- Critically ill patients requiring mechanical ventilation
- Improving survival in intensive care
- Supportive care and treatment optimization
- Broad clinical research across complex disease settings
Together, these studies show a diverse research program that extends beyond oncology into infection-related care and critical illness management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 35 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Humanitas Mirasole S.p.A.
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 35 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 11 | Unknown | 2020-12-01 | 2026-02-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.